• Crelux GmbH
  • Am Klopferspitz 19a
  • 82152 Planegg/Martinsried
  • Germany
  • Phone: +49 (0)89/700 760 0
  • Fax: +49 (0)89/700 760 222
  • moc.cetppaixuw@eciffo_xulerc

Dr. Gundel Hager
Geschäftsführerin / Managing Director

About Crelux

Crelux GmbH is a fruit of a mission to expedite structurebased drug discovery and deliver innovative solutions to the clients. This was the vision of founders Dr. Michael Schäffer, Dr. Martin Ried and late Dr. Ismail Moarefi. In 2016 Crelux GmbH was acquired by WuXi AppTec, a leading global solutions providing company that enables companies worldwide to advance discoveries and deliver groundbreaking treatments to patients. We provide broad services to support hit-finding, conformational analysis and lead optimization, including protein production, biophysical assays, fragment screening, screening of DNA-encoded libraries (DEL), and structural elucidation of biomolecular targets by X-ray crystallography, cryo-EM and NMR. Today, our vision is that “every drug can be made and every disease can be treated”.

What is your motivation?

Unmet medical needs and an increasing costs per new drug demand profoundly different models of research and discovery in drug development. Consequently, the pharmaceutical and biotech industry is entering an unprecedented era of innovations. The multidisciplinary target-to-hit platform of Crelux/WuXi AppTec HitS provides a wealth of knowledge bundled with the cutting-edge technologies, experienced scientists and technologist. We work closely with our clients, who are treated as partners. This system embraces agile teams, the vision of clients to find a cure for patients, and culminates in the innovation. The ultimate motivation of the entire Crelux team is to support our partners (from virtual companies to big pharma) in their effort to bring new medicines to patients much faster and efficient.

“The fact that IZB is a hub of cutting-edge technologies, centrally placed between University and Max Planck Institute, is a great asset for Crelux.”

Dr. Gundel Hager
Geschäftsführerin / Managing Director

Internationally Leading Partner for Drug Discovery Solutions

CRELUX, part of the Research Service Division of WuXi AppTec, is a global provider of structure-based drug discovery solutions. For more than a decade, we have been providing tailor-made and integrated services in drug discovery, structural analysis (crystallography, cryo-EM), protein production, biophysical characterization, fragment screening and DEL. CRELUX has successfully solved over a thousand protein structures for its international clients. Our Off-The-Shelf portfolio contains therapeutically relevant protein targets, whose co-crystal structures with drug candidates can be delivered to our clients within a few weeks.

An integrated technology platform, innovative expression systems and the integration of the comprehensive service portfolio of our parent company WuXi AppTec guarantee high success rates and attractive costs.